Deciphering the complex role of thrombospondin-1 in glioblastoma development.
Fiche publication
Date publication
mars 2019
Journal
Nature communications
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DEDIEU Stéphane
Tous les auteurs :
Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, Pineau R, Guérit S, Maitre M, Dedieu S, Jeanne A, Bailly S, Feige JJ, Miletic H, Rossi M, Bello L, Falciani F, Bjerkvig R, Bikfalvi A
Lien Pubmed
Résumé
We undertook a systematic study focused on the matricellular protein Thrombospondin-1 (THBS1) to uncover molecular mechanisms underlying the role of THBS1 in glioblastoma (GBM) development. THBS1 was found to be increased with glioma grades. Mechanistically, we show that the TGFβ canonical pathway transcriptionally regulates THBS1, through SMAD3 binding to the THBS1 gene promoter. THBS1 silencing inhibits tumour cell invasion and growth, alone and in combination with anti-angiogenic therapy. Specific inhibition of the THBS1/CD47 interaction using an antagonist peptide decreases cell invasion. This is confirmed by CD47 knock-down experiments. RNA sequencing of patient-derived xenograft tissue from laser capture micro-dissected peripheral and central tumour areas demonstrates that THBS1 is one of the gene with the highest connectivity at the tumour borders. All in all, these data show that TGFβ1 induces THBS1 expression via Smad3 which contributes to the invasive behaviour during GBM expansion. Furthermore, tumour cell-bound CD47 is implicated in this process.
Mots clés
Animals, Brain Neoplasms, blood supply, CD47 Antigen, antagonists & inhibitors, Cell Line, Tumor, Cerebral Cortex, Gene Expression Regulation, Neoplastic, Glioblastoma, blood supply, Humans, Laser Capture Microdissection, Male, Mice, Mice, Knockout, Neoplasm Invasiveness, Peptides, pharmacology, Promoter Regions, Genetic, Protein Binding, RNA, Small Interfering, genetics, Signal Transduction, Smad3 Protein, genetics, Spheroids, Cellular, metabolism, Survival Analysis, Thrombospondin 1, antagonists & inhibitors, Transforming Growth Factor beta1, genetics, Xenograft Model Antitumor Assays
Référence
Nat Commun. 2019 Mar 8;10(1):1146